Abstract
Eleven patients ranging in age from 2 to 16 years with documented bone and joint infections were treated with Ceforanide (C), an experimental cephalosporin antibiotic. Eight had osteomyelitis and 3 had joint infections. S. aureus was isolated from the blood or infection site in 7 of the patients, 5 with osteomyelitis and 2 with joint infections. One patient was treated for 3 weeks without a positive culture for a presumed septic joint. The patient improved during treatment but subsequently relapsed and was found to have H. influenzae osteomyelitis. No organism was isolated from 3 patients. One patient failed to improve within the first week. A blood culture during that time grew S. aureus and therapy was changed. Patients received C, 10-20 mg/kg/dose IV or IM every 12 hours. Six patients had received prior antibiotic therapy for periods ranging from 2 to 14 days. One patient receiving C experienced an urticarial rash following 6 days of treatment and was changed to another antibiotic. All S. aureus isolates were tested against C and found to be susceptible. Serum C levels and pharma-cokinetics were measured and confirmed the adequacy of the 12 hour dosing schedule. Treatment with C was successful in 8/11 patients with follow-up of 6-18 months. C is an effective antibiotic for the treatment of bone and joint infections caused by susceptible organisms. The 12 hour dosing interval offers a unique advantage in pediatric patients.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rodgers, G., Weiner, L., Mcmillan, J. et al. 1060 TREATMENT OF BONE AND JOINT INFECTION WITH CEFORANIDE-A NEW CEPHALOSPORIN ANTIBIOTIC. Pediatr Res 15 (Suppl 4), 619 (1981). https://doi.org/10.1203/00006450-198104001-01086
Issue Date:
DOI: https://doi.org/10.1203/00006450-198104001-01086